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Radical surgery versus organ preservation via short-course 
radiotherapy followed by transanal endoscopic microsurgery 
for early-stage rectal cancer (TREC): a randomised, 
open-label feasibility study
Simon P Bach, Alexandra Gilbert, Kristian Brock, Stephan Korsgen, Ian Geh, James Hill, Talvinder Gill, Paul Hainsworth, Matthew G Tutton, 
Jim Khan, Jonathan Robinson, Mark Steward, Christopher Cunningham, Bruce Levy, Alan Beveridge, Kelly Handley, Manjinder Kaur, 
Natalie Marchevsky, Laura Magill, Ann Russell, Philip Quirke, Nicholas P West, David Sebag-Montefiore, on behalf of the TREC collaborators*
Summary
Background Radical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage 
rectal cancer. An organ-preserving strategy with selective total mesorectal excision could reduce the adverse effects of 
treatment without substantially compromising oncological outcomes. We investigated the feasibility of recruiting 
patients to a randomised trial comparing an organ-preserving strategy with total mesorectal excision.
Methods TREC was a randomised, open-label feasibility study done at 21 tertiary referral centres in the UK. Eligible 
participants were aged 18 years or older with rectal adenocarcinoma, staged T2 or lower, with a maximum diameter of 
30 mm or less; patients with lymph node involvement or metastases were excluded. Patients were randomly 
allocated (1:1) by use of a computer-based randomisation service to undergo organ preservation with short-course 
radiotherapy followed by transanal endoscopic microsurgery after 8–10 weeks, or total mesorectal excision. Where the 
transanal endoscopic microsurgery specimen showed histopathological features associated with an increased risk of 
local recurrence, patients were considered for planned early conversion to total mesorectal excision. A non-randomised 
prospective registry captured patients for whom randomisation was considered inappropriate, because of a strong 
clinical indication for one treatment group. The primary endpoint was cumulative randomisation at 12, 18, and 
24 months. Secondary outcomes evaluated safety, efficacy, and health-related quality of life assessed with the European 
Organisation for Research and Treatment of Cancer (EORTC) QLQ C30 and CR29 in the intention-to-treat population. 
This trial is registered with the ISRCTN Registry, ISRCTN14422743.
Findings Between Feb 22, 2012, and Dec 19, 2014, 55 patients were randomly assigned at 15 sites; 27 to organ preservation 
and 28 to radical surgery. Cumulatively, 18 patients had been randomly assigned at 12 months, 31 at 18 months, and 
39 at 24 months. No patients died within 30 days of initial treatment, but one patient randomly assigned to organ 
preservation died within 6 months following conversion to total mesorectal excision with anastomotic leakage. 
Eight (30%) of 27 patients randomly assigned to organ preservation were converted to total mesorectal excision. Serious 
adverse events were reported in four (15%) of 27 patients randomly assigned to organ preservation versus 11 (39%) of 
28 randomly assigned to total mesorectal excision (p=0·04, χ² test). Serious adverse events associated with organ 
preservation were most commonly due to rectal bleeding or pain following transanal endoscopic microsurgery (reported 
in three cases). Radical total mesorectal excision was associated with medical and surgical complications including 
anastomotic leakage (two patients), kidney injury (two patients), cardiac arrest (one patient), and pneumonia 
(two patients). Histopathological features that would be considered to be associated with increased risk of tumour 
recurrence if observed after transanal endoscopic microsurgery alone were present in 16 (59%) of 27 patients randomly 
assigned to organ preservation, versus 24 (86%) of 28 randomly assigned to total mesorectal excision (p=0·03, χ² test). 
Eight (30%) of 27 patients assigned to organ preservation achieved a complete response to radiotherapy. Patients who 
were randomly assigned to organ preservation showed improvements in patient-reported bowel toxicities and quality of 
life and function scores in multiple items compared to those who were randomly assigned to total mesorectal excision, 
which were sustained over 36 months’ follow-up. The non-randomised registry comprised 61 patients who underwent 
organ preservation and seven who underwent radical surgery. Non-randomised patients who underwent organ 
preservation were older than randomised patients and more likely to have life-limiting comorbidities. Serious adverse 
events occurred in ten (16%) of 61 non-randomised patients who underwent organ preservation versus one (14%) 
of seven who underwent total mesorectal excision. 24 (39%) of 61 non-randomised patients who underwent organ 
preservation had high-risk histopathological features, while 25 (41%) of 61 achieved a complete response. Overall, organ 
preservation was achieved in 19 (70%) of 27 randomised patients and 56 (92%) of 61 non-randomised patients.
Interpretation Short-course radiotherapy followed by transanal endoscopic microsurgery achieves high levels of organ 
preservation, with relatively low morbidity and indications of improved quality of life. These data support the use of 
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Introduction
Radical surgical resection adhering to the principles of 
total mesorectal excision is the standard of care for 
localised rectal cancer, with selective use of pre-operative 
chemoradiotherapy reserved for patients with locally 
advanced disease.1 Although total mesorectal excision 
provides effective local tumour control, patients must 
accept a 2% mortality risk and the prospect of 
considerable short-term morbidity.2 Cancer survivors 
report long-term bowel, bladder, and sexual dysfunction 
following total mesorectal excision that impairs quality 
of life (QOL).3,4
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organ preservation for patients considered unsuitable for primary total mesorectal excision due to the short-term 
risks associated with this surgery, and support further evaluation of short-course radiotherapy to achieve organ 
preservation in patients considered fit for total mesorectal excision. Larger randomised studies, such as the ongoing 
STAR-TREC study, are needed to more precisely determine oncological outcomes following different organ 
preservation treatment schedules.
Funding Cancer Research UK.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Research in context
Evidence before this study
Radical surgery to remove the rectum, adhering to the principles 
of total mesorectal excision, without pre-operative 
radiotherapy, is the standard of care for early-stage rectal 
cancer. However, radical surgery has measurable mortality, 
substantial morbidity, and a considerable impact on patients’ 
quality of life (QOL). Patient groups and health-care 
professionals both recognise the potential benefits of an organ 
preservation approach for the treatment of early-stage rectal 
cancer to reduce the morbidity associated with radical surgery 
without compromising oncological outcomes, but there is 
currently a lack of high-quality, prospective, randomised 
evidence to justify adoption of this approach. Organ 
preservation strategies commonly use a combination of 
radiotherapy and local excision. The feasibility of primary organ 
preservation with chemoradiotherapy is not in doubt, but the 
cumulative toxicity arising from multiple treatments is 
problematic, particularly for patients who do not achieve organ 
preservation, and adversely affects patients’ health-related QOL 
(HRQOL). Furthermore, to the best of our knowledge, no 
randomised study has compared an organ preservation strategy 
with total mesorectal excision alone. The GRECCAR 2 trial 
enrolled patients with small T2 and T3 rectal cancer following a 
good clinical response to chemoradiotherapy, randomly 
assigning patients to undergo either radical surgery or transanal 
local excision (transanal endoscopic microsurgery). Conversion 
to radical surgery was advised for patients with ypT2 or more 
advanced stage cancer. A composite endpoint of death, cancer 
recurrence, and treatment-related morbidity at 2 years 
concluded that organ preservation was not superior to 
chemoradiotherapy plus radical surgery due to the cumulative 
toxicities of multiple treatments. Further exploratory analysis 
by treatment received suggested lower rates of faecal 
incontinence in patients who achieved organ preservation at 
2 years. Notably, few studies have reported longer-term toxicity 
rates or patient-reported outcomes including HRQOL following 
organ preservation, particularly in a randomised setting against 
total mesorectal excision surgery alone. This limits our ability to 
extrapolate available data on HRQOL to guide patient choices.
Added value of this study
The TREC study demonstrates the feasibility of randomly 
assigning patients with early-stage rectal cancer to a 
multimodality organ preservation strategy (incorporating 
short-course radiotherapy and transanal endoscopic 
microsurgery) versus radical surgery without radiotherapy. 
The comparison of organ preservation with radical surgery 
showed some benefits of organ preservation with respect to 
fewer serious surgical complications, low acute patient-
reported toxicity, and little impact on QOL and function at 
3 months. Sustained benefits for up to 3 years in overall QOL, 
social function, body image, and decreased embarrassment 
about bowel function were also observed with organ 
preservation. The risk of unsalvageable local recurrence was low 
in TREC.
Implications of all the available evidence
The findings of the TREC study suggest that short-course 
radiotherapy and transanal endoscopic microsurgery is 
associated with lower acute and late patient-reported side-
effects than total mesorectal excision (the standard of care), 
and consequently has a minimal impact on patients’ QOL. 
The high levels of compliance, low toxicity, significant 
downstaging, and high rates of organ preservation achieved in 
the TREC study support further evaluation of short-course 
radiotherapy to achieve primary organ preservation in patients 
with early-stage rectal cancer alongside other measures that 
could reduce the adverse effects of treatment, such as smaller 
risk-adapted radiotherapy fields, non-operative management of 
complete response, and a biomarker-driven approach to 
initiating surgical intervention. Such measures should be 
implemented in the context of well conducted clinical research, 
such as the ongoing STAR-TREC study, as larger randomised trials 
are required to establish the oncological safety of organ 
preservation.
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25% of total mesorectal excision operations done in 
the UK are for non-irradiated T1 and T2 rectal tumours.2 
Interest in primary organ preservation for early-stage 
rectal cancer is gathering momentum but there is a lack of 
high quality, prospective, randomised evidence to justify 
its adoption.5,6 Primary organ preservation in early-stage 
rectal cancer aims to preserve the rectum and its function. 
This approach can involve radiotherapy, local excision, or 
a combination of treatment approaches. Local transanal 
surgical excision of early-stage rectal cancer can achieve 
organ preservation, but overall oncological outcomes are 
compromised.1,7,8 The risk of local recurrence following 
transanal excision is associated with the presence of 
specific high-risk histopathological features that are only 
evaluable, and thereby appreciated, once the tumour is 
removed.8 Chemoradiotherapy followed by transanal local 
excision is an experimental approach to improve outcomes 
for primary organ preservation in early-stage rectal 
tumours, but multiple treatments can give rise to 
cumulative toxicities that detract from the benefits of 
organ preservation.9–11 The efficacy of pre-operative short-
course radiotherapy compared with chemoradiotherapy 
for prevention of local relapse is supported by two phase 3 
trials in patients with radically excised rectal cancer, where 
short-course radiotherapy showed benefits in terms of 
reduced toxicity.12,13 Short-course radiotherapy with delayed 
local excision provided safe and effective primary organ 
preservation in a cohort of frail, elderly patients with T1 
and T2 N0 rectal cancer,14 but excessive surgical morbidity 
was reported in another study.15
To our knowledge, TREC is the first study to randomly 
assign patients with early-stage rectal cancer to organ 
preservation (via short-course radiotherapy and delayed 
transanal endoscopic microsurgery) or radical surgery 
(total mesorectal excision) without preoperative chemo-
radiotherapy. TREC was designed to assess the feasibility 
of recruiting patients to a larger randomised phase 3 trial 
comparing these different treatment approaches.16 This 
study was designed to address the lack of randomised 
evidence describing the trajectory of symptomatic toxicity 
and health-related quality of life (HRQOL) following 
organ preservation and total mesorectal excision. The 
aim of the TREC study was to determine the feasibility of 
randomisation between two markedly different treatment 
options. We also aimed to explore the impact of the novel 
organ preservation intervention to inform the design of a 
larger phase 3 study comparing radical surgery with 
organ preservation.
Methods
Study design and participants
TREC was a randomised, open-label, feasibility study done 
in the UK, at 21 tertiary referral centres specialising in the 
treatment of early-stage rectal cancer. TREC assessed the 
feasibility of randomly assigning eligible patients with 
early-stage rectal cancer to either total mesorectal excision, 
without pre-operative radiotherapy in accordance with 
NICE guidance,6 or a novel organ preservation strategy. 
A non-randomised registry was included to capture 
treatment outcomes in patients for whom randomisation 
was considered inappropriate, due to a strong clinical 
indication for one of the treatment options (eg, individuals 
considered unsuitable for total mesorectal excision due to 
frailty, comorbidity, or older age).
Eligible patients were aged 18 years or older with rectal 
adenocarcinoma staged T2 or lower, no lymph node 
involvement (ie, N0), with a maximum diameter of 30 mm 
or less, and no metastasis. Patients with a previous history 
of pelvic radiotherapy were excluded. Participants provided 
written informed consent and the study was done in 
accordance with the Declaration of Helsinki and Good 
Clinical Practice Guidelines. The trial was approved by the 
West Midlands, Black Country Research Ethics Committee 
(10/H1202/81).
Randomisation and masking
All patients were reviewed by a colorectal cancer multi-
disciplinary team at each centre, and eligible patients who 
were considered equally suitable for total mesorectal 
excision or organ preservation were invited to enrol in the 
study and randomly assigned in a 1:1 ratio. Treatment 
allocation was done with a computer-based randomisation 
service accessed by telephone or web link. Patients and 
investigators were not masked to treatment allocation. 
Where the multidisciplinary team strongly preferred one 
of the two treatment groups the patients were invited to 
participate in the study via a non-randomised registry. 
Entry to the registry was by online or telephone registration 
before any treatment was initiated. At the outset of the 
study, eligible patients who declined randomisation were 
excluded from the study and offered standard treatment, 
but a protocol amend ment on May 8, 2013, allowed 
patients who were particularly reluctant to undergo radical 
surgery or formation of a stoma to choose organ 
preservation through the non-randomised registry.
Procedures
Baseline investigations included colonoscopy, tumour 
biopsy, high-resolution pelvic MRI, endorectal ultrasound 
(optional) and CT scan of the thorax, abdomen, and pelvis. 
Organ preservation consisted of three-dimensional pelvic 
conformal short-course radiotherapy followed by local 
excision. 25 Gy in five fractions was given over a period of 
5–7 days with photon energies of at least 6 MV and a three 
or four field technique. The clinical radiotherapy target 
volume included the tumour, mesorectum, and internal 
iliac, obturator and presacral nodes, up to the level of 
S2/3 junction. Radiotherapy quality assurance was 
coordinated by the UK National Cancer Research Institute 
Radiotherapy Trials Quality Assurance team.
After an interval of 8–10 weeks following completion of 
short-course radiotherapy the area of the rectal wall 
affected by cancer was removed, with a 10 mm margin of 
normal mucosa, via transanal endoscopic microsurgery. 
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Figure 1: Trial profile
*23 patients were randomly assigned to organ preservation while three crossed over from total mesorectal excision to organ preservation.



























152 eligible patients identified
55 patients randomly assigned29 patients did not enter study
27 allocated to organ
preservation
28 allocated to radical
surgery (total
mesorectal excision)
Protocol deviation: three patients
crossed  over from total mesorectal




25 received primary 
radical  surgery 
(total mesorectal 
excision)
Protocol deviation: three patients
crossed over to total mesorectal







2 patients initially assigned to
 radical surgery but who received
 organ preservation underwent
 total mesorectal excision
5 patients underwent early
per-protocol conversion to total
mesorectal excision
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The surgeon performed full thickness local disc excision of 
the tumour site, incorporating the muscularis propria with 
a small amount of mesorectal fat. Transanal endoscopic 
microsurgery specimens were pinned out, mucosal 
surface upwards, to identify the rim of surround ing 
normal tissue, before fixing intact. Standard radical 
surgery adhered to the principles of total mesorectal 
excision by low anterior resection or abdomino perineal 
excision where the primary tumour encroached upon the 
anal canal. Surgery comprised a minimally invasive, open, 
or hybrid approach. Specimens were classified according 
to TNM5, and pT1 cancers were substaged by the depth of 
the submucosal invasion. Central histopathological review 
was done for quality assurance and to score radiotherapy 
regression grade. Pathological complete response (ypT0) 
was designated by no visible tumour cells, despite 
embedding the entirety of the tumour and sectioning all 
blocks at three levels. Histopathological features con-
sidered high risk for local relapse following organ preser-
vation were a maximum tumour diameter greater than 
30 mm, cancer within 1 mm of the circumferential or deep 
resection margin, predominantly poor differen tiation, 
presence of lymphatic or venous invasion (intramural or 
extramural), and tumour depth of invasion of submucosal 
tumour stage 3 (sm3) or greater.8 Patients with one or 
more of these high-risk features were considered for 
planned early conversion from organ preservation to total 
mesorectal excision surgery within 8 weeks.
Patients were followed up in the clinic at 3, 6, 12, 24, 
and 36 months; with carcinoembryonic antigen testing 
at 12, 24, and 36 months; and CT scan of the thorax, 
abdomen, and pelvis at 12 and 24 months. Additionally, 
patients undergoing organ preservation had white light 
endoscopy and MRI scans every 3 months for 2 years, 
then every 6 months for up to 3 years.
Outcomes
The primary endpoint was cumulative recruitment of 
randomised patients, reported 12, 18, and 24 months from 
the date of first randomisation. Secondary endpoints 
comprised measures of safety, including 30-day and 
6-month mortality, clinician-reported morbidity (Common 
Terminology Criteria for Adverse Events [CTCAE], version 
4.0, reported 3 weeks after short-course radiotherapy and 
incidence of serious adverse events), patient-reported 
toxicity, and HRQOL assessed with validated European 
Organisation for Research and Treatment of Cancer 
(EORTC) QLQ C29 and C30 questionnaires measured at 
baseline, and at 3, 6, 12, 24, and 36 months in the intention-
to-treat population.17,18 Serious adverse events were defined 
as those that caused death, threat to life, prolonged hospital 
stay, readmission to hospital, or persistent disability. 
Secondary efficacy endpoints were tumour downstaging 
(including the incidence of histopathological features 
considered high risk for local recurrence following 
transanal excision alone), organ preservation rate, stoma 
rates, tumour recurrence, disease-free survival, overall 
survival, and HRQOL. Overall survival was calculated from 
the date of randomisation or registration to the date of 
death, and disease-free survival was calculated from the 
date of randomisation or registration to the date of death 













Age, years 65 (52–79) 65 (49–83) 74 (53–89) 69 (53–73)
Sex
Male 19 (70%) 17 (61%) 39 (64%) 4 (57%)
Female 8 (30%) 11 (39%) 22 (36%) 3 (43%)
ASA physical status classification
I 11 (41%) 13 (47%) 24 (39%) 4 (57%)
II 14 (52%) 11 (39%) 23 (38%) 2 (29%)
III 2 (7%) 4 (14%) 13 (21%) 0
Missing ·· ·· 1 (2%) 1 (4%)
Distance from lower border of tumour to anal 
verge, mm
60 (40–80) 60 (50–70) 60 (40–70) 55 (35–75)
Tumour position
Anterior 7 (27%) 10 (35%) 8 (15%) 1 (14%)
Lateral 14 (54%) 5 (18%) 20 (36%) 3 (43%)
Posterior 5 (19%) 12 (43%) 23 42%) 3 (43%)
Not known 0 1 (4%) 4 (7%) 0
MRI T stage
Tx 1 (4%) 2 (7%) 6 (10%) 0
T1 10 (37%) 5 (18%) 10 (16%) 0
T2 16 (59%) 21 (75%) 45 (74%) 7 (100%)
Ultrasound stage
Tx 0 0 1 (2%) 0
T1 9 (33%) 10 (36%) 16 (26%) 1 (14%)
T2 10 (37%) 9 (32%) 31 (51%) 4 (57%)
Not done 8 (30%) 9 (32%) 13 (21%) 2 (29%)
Sphincter preservation considered feasible
Yes 23 (85%) 25 (89%) ·· ··
No 4 (15%) 3 (11%) ·· ··
Compliance with treatment allocation 23 (85%) 25 (89%) 55 (90%) 7 (100%)
SCRT commenced 27 (100%) 3 (11%) 60 (98%) ··
SCRT completed 27 (100%) 3 (11%) 60 (98%) ··
Primary surgery
TEM 23 (85%) 3 (11%) 55 (92%) 0
Low anterior resection 3 (11%) 23 (82%) 0 7 (100%)
Abdominoperineal excision 0 2 (7%) 0 0
No surgery* 1 (4%) 0 5 (8%) 0
Temporary stoma 2 (7%) 20 (71%) 0 5 (71%)
Stoma for complications 1 (4%) 3 (11%) 2 1 (14%)
Planned early conversion to TME following 
organ preservation
5 (19%) 2 (7%) 4 (7%) ··
Second surgery (planned early conversion following TEM)
Low anterior resection 3 0 1 ··
Abdominoperineal excision 1 2 3 ··
Hartmann’s 1 0 0 ··
Temporary stoma 3 0 1 ··
(Table 1 continues on next page)
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or disease recurrence, whichever occurred first. The site of 
recurrence at first relapse was grouped as isolated local 
(pelvic), local plus distant, or isolated distant, to determine 
recurrence-free survival.
Statistical analysis
Statistical analysis was done at Birmingham Cancer 
Research UK Clinical Trials Unit and Birmingham 
Clinical Trials Unit with R software (version 3.5.2). TREC 
assessed the feasibility of developing multidisciplinary 
organ preservation teams, opening sites, and recruiting 
patients to a randomised trial design. The study was not 
formally powered for a cancer outcome and no a-priori 
recruitment target was set. The secondary endpoint of 
tumour downstaging was selected to show the effect size 
needed to produce a significant difference between 
randomised groups in the intention-to-treat population. 
As preoperative short-course radiotherapy reduces local 
recurrence after total mesorectal excision by 50%,19 we 
hypothesised that short-course radiotherapy with an 
interval of 8–10 weeks to transanal endoscopic micro-
surgery would reduce the incidence of high-risk histo-
pathological features by 50% or more compared 
with non-irradiated, radical surgery. Histopathological 
features that were considered high risk for local 
recurrence were derived from previous studies in 
patients treated with transanal endoscopic microsurgery 
alone, as were estimates of prevalence.8 46 randomised 
patients were required to show that short-course 
radiotherapy reduced the incidence of high-risk features 
from 75% to 35% (α=0·05, 80% power, one-tailed). 
Binary proportions were compared across randomised 
groups by χ² test. Survival outcomes were estimated with 
the Kaplan-Meier method and randomised groups were 
compared with the log-rank test. Patients without the 
event in each outcome were censored at the last known 
event-free time. Outcomes for the non-randomised 
population are provided for hypoth esis generation. 
Completion of patient-reported outcomes, and item 
and scale compliance were determined. EORTC-QLQ 
guidelines were used for analyses and management of 
missing data.20 All item responses were converted from a 
four-point Likert-type scale with linear transformation 
onto a 0–100 scale.20 Differences in mean scores were 
classified as a small change for 5–10 points, a moderate 
change for 10–20 points, or a large change for more than 
20 points.21 Exploratory item-level probabilities of the 
reported benefit or detriment of an organ-sparing 
approach compared to radical surgery were calculated for 
each patient-reported outcome assessment point with a 
Bayesian model-based analysis, adjusting for assessment 
time, treatment allocation, and baseline patient-reported 
outcome score. Trial oversight was main tained by a 
combined trial steering committee and data monitoring 
committee.
This trial is registered with the ISRCTN Registry, 
ISRCTN14422743.
Role of the funding source
Cancer Research UK reviewed, approved, and funded the 
study design (CRUK/09/032). The funder played no part 
in study design, data analysis, or writing of this report. 
SPB, KB, AG, NM, MK, LM, KH, DSM, PQ, and NPW 
accessed and verified the data. All authors had full access 
to all trial data and had final responsibility for the decision 
to submit for publication.













(Continued from previous page)
Overall stoma rate
Permanent 2 (7%) 4 (14%) 3 (5%) 0
Temporary 6 (22%) 23 (82%) 3 (5%) 6 (86%)
Organ preservation rate 19 (70%) 1 (3%) 56 (92%) 0 (0%)
ASA=American Society of Anesthesiologists. SCRT=short-course radiotherapy. TEM=transanal endoscopic microsurgery. 
TME=total mesorectal excision. *No TEM done following complete clinical response of the primary tumour.
Table 1: Baseline characteristics and treatment of intention-to-treat population













30-day mortality 0 0 0 0
6-month mortality 1* 0 0 0
All serious adverse events 5 15 15 1
Number of patients with a serious adverse event† 4 (15%) 11 (39%) 10 (16%) 1 (14%)
Cause of serious adverse events reported
Abdominal pain 0 0 1 0
Acute kidney injury 0 2 0 0
Anastomotic leak 1* 2 2 1
Anastomotic stricture 0 1 0 0
Cardiac arrest 0 1 0 0
Cardiac failure 0 0 1 0
Diarrhoea 1 1 2 0
Deep venous thrombosis 0 1 0 0
Fever 0 0 1 0
Fistula 0 0 1 0
Incisional hernia 0 1 0 0
Pancreatitis 0 1 0 0
Paralytic ileus 0 1 1 0
Pneumonia 0 2 2 0
Rectal bleed 2 1 2 0
Rectal pain 1 0 0 0
Stoma oedema 0 1 0 0
Stroke 0 0 2 0
Serious adverse events are classified as complications leading to either death, threat to life, prolonged hospital stay, 
readmission to hospital, or persistent disability. *Primary surgery was low anterior resection. †Comparison of 
proportion of randomised patients with one or more serious adverse events (p=0·04, χ² test).
Table 2: Serious adverse events in the intention-to-treat population
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Results
152 eligible patients with early-stage rectal cancer were 
identified at 21 UK sites; 14 recruiting sites opened during 
year 1, and seven sites joined during year 2. 123 (81%) 
patients entered the TREC study, whereas 29 declined 
(figure 1). Between Feb 22, 2012, and Dec 19, 2014, 
55 patients consented to randomisation at 15 sites 
(appendix p 8); 27 patients were allocated to organ preser-
vation and 28 to radical surgery (figure 1). Cumulative 
recruitment to the ran domised study was as follows: 
18 patients at 12 months, 31 at 18 months, 39 at 24 months, 
and 55 at 36 months. The date for final follow-up was 
April 19, 2018. Randomised patients were generally well 
matched in terms of age, sex, American Society of 
Anesthesiologists (ASA) physical status classification, and 
tumour stage (table 1). 68 patients were recruited to the 
non-randomised registry at 17 sites, with organ preser-
vation preferred in 61 patients and radical total mesorectal 
excision surgery in seven (figure 1). Non-randomised 
patients who underwent organ preser vation were 
generally older than randomised patients, more likely to 
have life-limiting comorbidities, and more often had 
T2 tumours (table 1). Six of 21 sites contributed non-
randomised patients only. All sites that recruited more 
than three patients to TREC included patients for 
randomisation (appendix p 8).
Compliance with the organ preservation treatment 
strategy was high for both randomised (23 [85%] of 
27 patients) and non-randomised groups (55 [90%] of 61; 
table 1). Short-course radiotherapy was well tolerated, with 
four (15%) of 27 patients having one or more grade 3 
adverse event, of which diarrhoea was the most common 
(appendix p 1). Three patients who were randomly 
assigned to total mesorectal excision refused this 
treatment allocation and instead received the organ 
preservation treatment (protocol deviation); two of these 
three patients reverted back to total mesorectal excision 
following transanal endoscopic microsurgery due to the 
presence of histopathological features con sidered high 
risk for local recurrence (figure 1). Patients randomly 
assigned to undergo primary total mesorectal excision 
were most frequently reconstructed by low anterior 
resection (23 [82%] of 28), with a temporary diverting 
stoma (20 [71%] of 28; table 1). The rate of abdomino-
perineal excision with total mesorectal excision was 14% 
(four of 28 patients) in the intention-to-treat population. 
Serious adverse events were reported in four (15%) of 
27 patients randomly assigned to organ preservation 
versus 11 (39%) of 28 randomly assigned to radical surgery 
(table 2; p=0·04, χ² test). One patient allocated to organ 
preservation who had total mesorectal excision as the first 
surgery (no transanal endoscopic microsurgery) died 
following anastomotic leakage (ypT2N0). Serious adverse 
events were reported for ten (16%) of 61 non-randomised 
patients allocated to undergo organ preservation and 
one (14%) of seven allocated to undergo total mesorectal 
excision (table 2).
Organ preservation was achieved in 19 (70%) of 
27 randomised patients and 56 (92%) of 61 non-randomised 
patients (table 1). Three patients (staged ypT1sm2N0, 
ypT1sm3N0, and ypT2N0) randomly assigned to organ 














0 7 (26%) 0 20 (33%) 0
1 6 (22%) 14 (50%) 18 (30%) 1 (14%)
2 8 (30%) 13 (46%) 12 (20%) 6 (86%)
3 5 (19%) 1 (4%) 4 (7%) 0
x 0 0 1 (2%) 0
Clinical complete response with no surgery 1 (4%) 0 5 (8%) 0
All cases with a complete response 8 (30%) 0 25 (41%) 0
Kikuchi substaging of pT1 tumours
Submucosal tumour stage 1 2 (33%) 2 (14%) 7 (39%) 0
Submucosal tumour stage 2 1 (17%) 3 (21%) 6 (33%) 0
Submucosal tumour stage 3 3 (50%) 9 (64%) 5 (38%) 1 (100%)
TNM pN stage
0 3 (11%) 23 (82%) 0 7 (100%)
1 0 3 (10%) 0 0
2 0 1 (4%) 0 0
x 24 (89%) 1 (4%) 60 (100%) 0
Surgical resection margin <1 mm
Clear 23 (85%) 26 (93%) 49 (82%) 7 (100%)
Involved adenoma 0 1 (4%) 1 (2%) 0
Involved carcinoma (deep) 3 (11%) 1 (4%) 1 (2%) 0
Involved carcinoma (mucosal) 0 0 0 0
No surgery 1 (4%) 0 5 (8%) 0
Missing 0 0 4 (6%) 0
Positive lymphatic invasion 0 5 (18%) 1 (2%) 1 (14%)
Positive vascular invasion 2 (8%) 7 (25%) 4 (7%) 0
Tumour differentiation
Well or moderately differentiated 17 (63%) 26 (93%) 31 (51%) 7 (100%)
Poorly differentiated 2 (7%) 2 (7%) 3 (5%) 0
Pathological complete response 7 (26%) 0 19 (31%) 0
Complete response* 1 (4%) 0 5 (8%) 0
Tumour diameter, mm 3 (0–17) 10 (0–30) 4 (0–45) 8 (2–30)
Radiotherapy response (Dworak 5-point system)
Complete 7 (26%) 0 19 (31%) ··
Good 5 (19%) 2 (67%) 15 (25%) ··
Moderate 6 (22%) 0 7 (11%) ··
Mild 4 (15%) 0 4 (7%) ··
No surgery 1 (4%) 0 5 (8%) ··
Missing 3 (11%) 1 (33%) 5 (8%) ··
High-risk histopathological feature 
present†
16/27 (59%) 24/28 (86%) 24/61 (39%) 7/7 (100%)
*Including pathological and clinical complete response. †Comparison of proportion of randomised patients with 
one or more histopathological feature considered high risk for relapse following local excision (maximum tumour 
diameter >30 mm, R1 resection, predominantly poor differentiation, presence of lymphatic or venous invasion and 
depth of invasion ≥submucosal tumour stage 3; p=0·03, χ² test). 
Table 3: Histopathological tumour characteristics
Articles
www.thelancet.com/gastrohep   Vol 6   February 2021 99
preservation underwent total mesorectal excision by low 
anterior resection following short-course radiotherapy 
without undergoing transanal endoscopic microsurgery 
(protocol deviations); in one, the transanal endoscopic 
microsurgery equipment could not reach the tumour, 
while in the other two the tumour was considered too large 
for transanal endoscopic microsurgery. Early per-protocol 
conversion from organ preservation to total mesorectal 
excision followed histopathological evaluation of the 
transanal endoscopic microsurgery specimen in five (19%) 
of 27 patients (table 1); there was no evidence of residual 
tumour in three patients, while two were staged ypT2N0.
Histopathological evaluation of randomised transanal 
endoscopic microsurgery specimens revealed that 
seven (26%) of 27 patients achieved a pathological 
complete response, and one achieved a clinical complete 
response (without transanal endoscopic microsurgery); 
therefore, eight (30%) of 27 patients randomly assigned 
to organ preservation achieved a complete response 
(table 3). The remaining patients were staged pT1 
(six [22%] of 27), pT2 (eight [30%] of 27), and pT3 
(five [19%] of 27). Of the 26 patients who underwent 
resection, resection margins were clear of cancer in 
23 (88%) cases; three (12%) demonstrated adeno car-
cinoma up to 1 mm of the deep margin. Histopatho-
logical examination revealed that 14 (50%) of 28 patients 
randomly assigned to total mesorectal excision (ie, who 
did not undergo radiotherapy) were pT1, 13 (46%) 
of 28 were pT2, and one (4%) of 28 was pT3 (table 3). 
Microscopic lymph node metastasis was detected in 
four (14%) of 28 patients. Resection margins were clear 
of cancer (≥1 mm) in 26 (96%) of 27 patients who had 
total mesorectal excision; an abdominoperineal excision 
was R1 at the circumferential margin. Histopathological 
features that would be considered high risk for local 
tumour recurrence if present following transanal 
endoscopic microsurgery alone were present in 24 (86%) 
of 28 patients randomly assigned to radical surgery 
Figure 2: Overall survival and disease-free survival for randomised and non-randomised populations
(A) Overall survival in the randomised population. (B) Overall survival in the non-randomised population. (C) Disease-free survival in the randomised population. 


















































































Kaplan-Meier overall survival estimates at 3 years:
Radical surgery 93% (95% CI 83–100)
Organ preservation 88% (95% CI 77–100)
p=0·35
Kaplan-Meier disease-free survival estimates at 3 years:
Radical surgery 85% (95% CI 73–100)
Organ preservation 76% (95% CI 60–95)
p=0·12
Kaplan-Meier disease-free survival estimates at 3 years:
Radical surgery 100% 
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(ie, who did not undergo radiotherapy), versus 16 (59%) 
of 27 randomly assigned to organ preservation (p=0·03, 
χ² test; table 3). 25 (41%) of 61 non-randomised patients 
who underwent organ preservation achieved a complete 
response, while high-risk histopathological features were 
present in 24 (39%) of 61 (table 3).
Median follow-up of randomised patients was 
4·28 years (IQR 3·27–5·02). There was no significant 
difference between randomised groups with respect to 
either overall survival (hazard ratio [HR] 1·95 [95% CI 
0·47–8·16]; p=0·35) or disease-free survival (2·32 
[0·77–6·95]; p=0·12; figure 2). Local recurrence occurred 
in three (11%) of 27 patients randomly assigned to organ 
preservation and was isolated and technically salvageable 
in two (7%) of 27 patients; however, severe cardiovascular 
comorbidity prohibited surgical salvage in one individual 
(appendix p 2). All three patients who developed local 
recurrence had previously declined planned conversion 
to total mesorectal excision despite having high-risk 
transanal endoscopic microsurgery features: ypT3 in two 
patients and R1 in one patient (appendix p 2). No 
instances of local recurrence were recorded following 
primary total mesorectal excision. Isolated systemic 
metastasis developed in three (11%) of 27 patients 
allocated to organ preservation versus two (7%) of 28 
allocated to total mesorectal excision (appendix p 2). 
Median follow-up of non-randomised patients was 
4·07 years (IQR 3·19–4·69). Local recurrence occurred in 
six (10%) of 60 non-randomised patients allocated 
to organ preservation; recurrence was isolated in 
three patients (appendix p 3). Systemic recurrence 
developed in six (10%) of 60 non-randomised patients 
allocated to organ preservation. The proportion of patients 
free from local recurrence at 3 years following organ 
preservation was 91% (95% CI 79–100) in the randomised 
population and 91% (84–99) in the non-randomised 
population (figure 3).
Patient allocation and patient-reported outcome com-
pletion rates for randomised patients are provided in the 
appendix (p 9). Compliance with patient-reported out-
comes was good (78·5% median completion rate; 
64·0% 36-month response rate), with no difference in 
response rates or missing items between groups. Key 
patient-reported outcome data are presented for ran-
domised patients in figure 4. A full summary of each 
patient-reported outcome item at each timepoint for 
randomised patients is provided in the appendix (pp 4–5), 
including a Bayesian model-based analysis (appendix p 6). 
Baseline questionnaires were completed following ran-
domi sation and patients had knowledge of their treatment 
allocation. Differences at baseline favoured organ 
preservation, for emotional (difference of 11·6 points) 
and role function (difference of 10·3 points), body image 
(difference of 18·5 points), and health anxiety (difference 
of 21·3 points).
During follow-up, patients randomly assigned to total 
mesorectal excision reported a deterioration in function 
scores at 3 months, with moderate differences between 
the two randomised groups favouring organ preservation 
for overall QOL, health anxiety, and physical, social, and 
role function (figure 4A–D). Patients randomly assigned 
to total mesorectal excision also demonstrated persistent 
moderate or large deteriorations in overall QOL, health 
anxiety, and role and social function, compared to 
baseline. The low body image scores noted preoperatively 
in the total mesorectal excision group at randomisation 
deteriorated further at 3 months and subsequently did 
not demonstrate recovery up to 36 months (figure 4E). 
Patients randomly assigned to organ preservation did not 
have any significant deterioration in pre-treatment QOL, 
health anxiety, and function (physical, role, social, 
emotional, and cognitive) over the 36-month study 
Figure 3: Cumulative risk of any local recurrence compared to risk of any recurrence (local or distant) with 
organ preservation therapy in intention-to-treat population 





































Kaplan-Meier estimates at 3 years:
Local recurrence: 91% (95% CI 79–100) 
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Figure 4: Change in EORTC 
QLQ C30 and CR29 over time 
for randomised patients
Data are mean (95% CI). 
(A) Quality of life. (B) Physical 
functioning. (C) Role 
functioning. (D) Social 
functioning. (E) Body image. 
(F) Impotence. (G) Sexual 
interest (female). (H) Sexual 
interest (male). (I) Diarrhoea. 
(J) Embarrassment about 
bowel function. (K) Faecal 
incontinence. (L) Stool 
frequency. EORTC=European 








































































































































































































































































































Short-course radiotherapy followed by transanal
endoscopic microsurgery
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period. Minimal change in body image scores occurred 
in the organ preservation group and a large difference 
persisted compared with total mesorectal excision at 
36 months (difference of 25·7 points).
For symptom items, there were no baseline differences 
in score (figure 4F, I–L). Compared with the organ 
preservation group, patients randomly assigned to total 
mesorectal excision showed a deterioration at 6 months in 
stool frequency, flatulence, incontinence, abdominal pain, 
and embarrassment about bowel function. Differences 
persisted at 36 months for overall stool frequency 
(difference of 16·3 points; figure 4L), stool frequency at 
night (difference of 25·4 points), and embarrassment 
about bowel function (difference of 31·7 points; figure 4J) 
in favour of organ preservation. There was also a moderate 
increase from baseline diarrhoea scores at 36 months for 
patients randomly assigned to total mesorectal excision 
(increase of 13·4 points) in comparison with those 
assigned to organ preservation (decrease of 6·8 points; 
figure 4I). Notably, the scores in the total mesorectal 
excision and organ preservation groups for faecal 
incontinence and flatulence were relatively similar at 
36 months, with both groups reporting relatively mild 
symptoms (figure 4K). Urinary symptoms, including 
frequency and incontinence, remained stable during 
follow-up. Impotence scores deteriorated from baseline to 
36 months (figure 4F) in both the randomised total 
mesorectal excision group (increase of 32·1 points) and 
the randomised organ preservation group (increase of 
17·1 points). No marked changes occurred in female 
sexual items (figure 4G). The benefit of organ preservation 
in patient-reported outcome scores was supported by an 
exploratory Bayesian model-based analysis (appendix p 6). 
Higher probabilities towards benefit for organ preservation 
were observed with organ preservation in many items at 
baseline, as noted previously. Inferences were adjusted for 
baseline values. At 36 months there was a 90% or greater 
probability of superiority for organ preservation in many 
patient-reported outcome items, including overall QOL; 
role, social, and emotional function; body image; health 
anxiety; diarrhoea; stool frequency; embarrassment about 
bowel function; and urinary incontinence.
Discussion
The TREC study demonstrates that it is feasible to 
randomly assign patients with early-stage rectal cancer to 
two markedly different treatment options: multimodality 
organ preservation treatment or total mesorectal excision 
with no preoperative radiotherapy. 81% of eligible patients 
approached for TREC took part and 36% were randomly 
assigned, highlighting the acceptability of an organ 
preservation approach if it is offered. All sites that 
included more than three patients were able to randomly 
assign patients, suggesting that clinical teams effectively 
adapted conventional clinical consultations to randomly 
assign patients to a study comparing two substantially 
different treatment approaches. The high proportion of 
non-randomised patients allocated to organ preservation 
indicates that referral patterns to specialist organ 
preservation practices were well established for frail, 
elderly, comorbid, and stoma-averse individuals with 
early-stage rectal cancer but underdeveloped in the wider 
patient population considered suitable for total mesorectal 
excision. Importantly, TREC was designed as a feasibility 
study, to introduce and evaluate a protocolised, multi-
modality organ preservation approach. The primary aim 
was to determine whether patients and clinicians would 
support randomisation between radical surgery and 
organ preservation, with secondary aims relating to 
safety, efficacy, and acceptability—key elements to inform 
the design of a future phase 3 trial.
Recent systematic reviews do not support adoption of 
an organ preservation approach for treatment of early-
stage rectal cancer in fit patients because of insufficient 
high quality evidence.22,23 In comparison with previous 
studies of chemoradiotherapy, the organ preservation 
approach followed in the TREC study has a number of 
strengths; we reported higher radiotherapy compliance 
(99% in randomised and non-randomised patients) than 
with chemo radiotherapy in previous studies (72–89%) 
and low acute toxicity (grade 3 adverse events: 
15% vs 10–42%), alongside favourable organ preservation 
and complete response rates.10,11,24 The low acute toxicity 
rate is not only reflected by clinician-reported monitoring 
of serious adverse events, but importantly also by 
prospective assess ment of patient-reported outcomes. As 
a feasibility study, TREC was not powered to undertake 
formal comparisons of specific long-term cancer outc-
omes, but the sample size allowed exploratory evaluation 
of downstaging of histopathological features that would 
be considered high risk for local recurrence if present 
following transanal endoscopic micro surgery alone.8 
Introduction of short-course radio therapy with an interval 
of 8–10 weeks to transanal endoscopic microsurgery was 
associated with significant tumour downstaging, corrobo-
rating an earlier report.25
To the best of our knowledge, we have, for the first 
time, shown consistent indications of benefit in multiple 
aspects of HRQOL and patient-reported toxicity with an 
organ preservation approach compared with total 
mesorectal excision alone, for up to 3 years. The risk of 
serious adverse events was lower with an organ preser-
vation approach (15%) than with total mesorectal 
excision (39%), which is the current standard of care. 
The organ preservation rates observed with short-course 
radiotherapy are equivalent to those observed in other 
studies evaluating chemoradiotherapy and transanal 
endo scopic microsurgery.10,24,26 Results from non-
randomised patients who underwent organ preservation, 
who were a decade older with increased comorbidities, 
were consistent with those obtained from the randomised 
patient population and also in accordance with our 
previous experience of using short-course radiotherapy 
and transanal endoscopic microsurgery to achieve organ 
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preservation in elderly and frail patients.14 Several studies 
of organ preservation have recorded severe treatment-
related toxicities that might be poorly tolerated in an 
older, frail patient population and so it was reassuring 
that in our study the tolerability and toxicity of short-
course radiotherapy and transanal endoscopic micro-
surgery did not seem to be any worse for this group.24,27 
The high rates of organ preservation for non-randomised 
patients might reflect a clear reticence for total mesorectal 
excision to be either offered or accepted. It is likely that 
the threshold for converting patients to total mesorectal 
excision in the non-randomised organ preservation 
group was higher than in the randomised group as non-
randomised patients were generally older, with comor-
bidities. Notably, this discrepancy in conversion rates did 
not lead to a marked increase in local recurrence. Future 
studies need to address the best approach to manage the 
decision to convert patients to total mesorectal excision.
Short-course radiotherapy and transanal endoscopic 
microsurgery, after an interval of 8–10 weeks, led to 
30% of randomised patients and 41% of non-randomised 
patients achieving a complete response, which is similar 
to studies of chemoradiotherapy where 40–45% of 
patients achieved a complete response.26,27 A 10-week 
interval from short-course radiotherapy to transanal 
endoscopic microsurgery was chosen to balance the 
potential benefits of waiting longer for optimal tumour 
regression with the risk of disease progression through 
treatment delay in a small proportion of patients who 
might be resistant to radiotherapy. At the inception of the 
TREC study the benefits of a good histopathological 
tumour response were appreciated,28 and the available 
evidence suggested that short-course radiotherapy 
produced downstaging after an interval to surgery of 
10 days or more;25 however, the optimal timing for 
assessment of radiotherapy response was unknown. 
TREC used transanal endoscopic micro surgery routinely, 
as did other contemporary studies following reports of 
extremely poor correlation between clinical and histo-
pathological staging in the context of a relatively short 
interval between radiotherapy and radical surgery.29 
Emerging data on the oncological safety of non-operative 
approaches to rectal cancer treatment,30,31 combined with 
the high complete response rates observed in this study 
and others,10,24,26 suggest that the adoption of a watch-and-
wait strategy with selective use of transanal endoscopic 
microsurgery is feasible with the aim of further reducing 
treatment-related toxicity and improving HRQOL.16 
However, the small sample size of TREC and the low 
number of events preclude meaningful analysis of 
oncological outcomes. We found no significant difference 
in either overall survival or disease-free survival between 
patients randomly assigned to organ preservation versus 
those randomly assigned to total mesorectal excision, in 
line with the GRECCAR 2 study,11 with very wide 
confidence intervals for the hazard ratios, reflecting the 
small sample size and relatively small number of events. 
A consistent proportion of patients relapse with distant 
metastasis regardless of primary therapy.11,32 Isolated and 
technically salvageable local recurrence was detected in 
two (7%) of 27 patients randomly assigned to organ 
preservation, each associated with strong histological 
indicators for early conversion to total mesorectal excision 
(ypT3R0 and ypT2R1), but the patients had declined early 
conversion to total mesorectal excision and opted for 
close observation. Local recurrence might have been 
avoided with early conversion. These data emphasise the 
need for a phase 3 trial to more precisely define the risks 
and benefits associated with adopting an organ preser-
vation approach.
Despite the small patient numbers, the patient-reported 
outcomes data reveal that an organ preservation approach 
is associated with consistent improvements in multiple 
symptom and function items 3 months after treatment, 
with longer-term benefits for overall QOL, social function, 
body image, and less embarrassment about bowel 
function. We found no evidence of acute deterioration 
in HRQOL or patient-reported toxicity with organ 
preservation versus total mesorectal excision.10,15,24 This 
exploratory analysis supports favourable longer-term 
patient-reported outcome scores seen at 1-year, 2-year, 
and 5-year follow-ups after organ preservation in various 
trials.10,33 Our data provide an important contribution to 
the literature due to the absence of published randomised 
studies comparing patient-reported outcomes following 
total mesorectal excision and organ preservation. 
Although an unexpected finding, the lower baseline 
mean scores in a number of function items for the radical 
surgery group (completed after knowledge of randomi-
sation status) might reflect our impression that the 
perceived risks of surgery in early-stage rectal cancer are 
higher than patients desire.
As a feasibility study, TREC provides the justification 
to further evaluate short-course radiotherapy and 
transanal endoscopic microsurgery versus radical 
surgery in a randomised setting. Although randomisation 
was feasible, our recruitment rate across centres 
indicated that recruitment to a future phase 3 trial 
should be international. Around the same time as the 
TREC study, a single-arm phase 2 trial done in the 
Netherlands (CARTS) had evaluated chemoradiotherapy 
followed by transanal endoscopic microsurgery.9 These 
studies provided the basis for the design of an inter-
national phase 2/3 trial (STAR-TREC) designed to 
randomly assign patients to radical surgery, organ 
preservation with short-course radiotherapy, and organ 
preservation with chemo radiotherapy.16 The external 
pilot (phase 2) demonstrated that it was possible to 
accelerate recruitment and the study progressed to 
phase 3 in 2020. The adoption of a more selective use of 
transanal endoscopic microsurgery, and a longer time 
interval to assess response in STAR-TREC were based 
on new data that became available after the completion 
of recruitment to TREC.
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Our findings have some limitations: in a feasibility 
study the overall numbers of randomised patients are 
low and individual centres contributed relatively few 
patients. However, recruitment of a randomised patient 
population has considerable strengths and reduces many 
sources of bias. This dataset will help inform the choices 
of patients who would normally receive standard total 
mesorectal excision and are considering the option to 
undergo organ preservation instead. The non-randomised 
registry primarily set out to describe the tolerability of 
treatment and early outcomes for older individuals 
considered to be at high risk for total mesorectal excision 
as this population is generally under-represented in 
rectal cancer trials. Although eligibility for inclusion was 
identical to the randomised group, the results should not 
be directly extrapolated to patients considered fit for total 
mesorectal excision. It is nonetheless reassuring that 
consistent trends were demonstrated across both ran-
domised and non-randomised populations following 
novel organ preservation therapy with short-course 
radiotherapy and transanal endoscopic microsurgery. 
Although the use of routine transanal endoscopic micro-
surgery might now be considered over-treatment, at the 
time of the design of TREC, there were little data to 
support the long-term oncological safety of a watch-and-
wait strategy, and there were concerns that short-course 
radiotherapy and treatment delay without transanal 
endoscopic micro surgery represented significant under-
treatment.
We conclude that TREC provides evidence to support 
further evaluation of organ preservation strategies that 
incorporate short-course radiotherapy as an alternative to 
radical surgery for early-stage rectal cancer. This is a 
feasible and acceptable approach for patients. Further 
evaluation of short-course radiotherapy is justified 
because of the excellent compliance, low toxicity, benefits 
in HRQOL, and high organ preservation rates observed in 
TREC. It is important that organ preservation con tinues to 
be evaluated in the context of well-conducted clinical 
research to establish the oncological safety of this 
approach.16
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